Jake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics, and serves on its Board of Directors. Together with colleagues at MIT’s renowned Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, the Boston Business Journal, and BioCentury, among others, for his vision and mission at Strand of applying this unique platform for real world disease applications. He has also been the recipient of prestigious national and international awards for his scientific and entrepreneurial achievements, including the Barry Goldwater Scholarship and Excellence in Education Award, the Andrew Viterbi Fellowship of MIT, Amgen Fellowship, and the Bristol-Myers Squibb 2018 Golden Ticket for recognition of Strand as an innovative startup. Beyond his work at Strand, Jake’s broader interests span synthetic biology, biologically engineered organism-machine interfaces, and the intersection of tech and biotech methodologies. He is an advocate among the life science entrepreneurial ecosystem for supporting young founders in biotech entrepreneurship. Currently, he serves on the advisory board of Starlight Ventures, an early stage venture firm, and also serves on the Executive Board of Public Health United, a non-profit focused on helping scientists better communicate their research for maximum impact. Previously, he served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. Jake received his Ph.D. in Biological Engineering and Synthetic Biology from MIT and his B.S. in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. He is an author or inventor on numerous high profile publications, patents and white papers, including in top tier journals such as Nature Chemical Biology and PNAS.
Tasuku Kitada is President and Head of R&D of Strand Therapeutics. He co-founded Strand and serves on its Board of Directors. Prior to Strand, Tasuku was Senior Biotechnology Analyst at Candriam Investors Group, where he conducted due diligence for the company’s multi-billion-dollar biopharma public equity investment strategy. At Candriam, he focused on cell and gene therapy companies, and also covered numerous oncology companies. Currently, Tasuku continues to serve Candriam Investors Group as an advisor. Prior to Candriam, Tasuku was a researcher at the Synthetic Biology Center at Massachusetts Institute of Technology where he became the first scientist to create synthetic gene circuits using synthetic mRNA. This was the first demonstration of post-transcriptional circuits that can be “wired” to create a variety of networks of increasing complexity, which enabled cell type specific expression as well as small-molecule based control of gene expression from synthetic mRNA. This important research led to publications in Science, Nature Biotechnology, and Nature Chemical Biology. The mRNA synthetic biology platform developed from this research has been exclusively licensed to Strand. Tasuku holds a Ph.D. in Molecular Biology from University of California, Los Angeles and a B.S. in Biophysics and Biochemistry from University of Tokyo.
Samta Kundu is the Chief Operating Officer of Strand Therapeutics. She has nearly three decades of business strategy and operations experience spanning pharma and biotech. She spent over a decade at Bristol-Myers Squibb (BMS), and was a member of the leadership team of Molecular Discovery Technologies, a department within BMS’ Discovery organization. During her tenure at BMS, she also led initiatives to increase the company’s visibility in the Cambridge/Boston life science community to support the opening of BMS' Cambridge R&D site. A key initiative she launched and executed was the company’s “Golden Ticket” contest to award lab space to innovative local startups, of which Strand was a 2018 winner. Previously, Samta was in business development at Adnexus Therapeutics, acquired by BMS in 2007, where she supported deal execution, management of the IP portfolio, and diligence operations. Post BMS acquisition, Samta led business operations for the newly acquired Adnexus-BMS site and executed a number of research transactions on behalf of the site. Earlier in her career, Samta held business development roles at Dyax and Consensus Pharmaceuticals, and was a project manager at Genzyme Tissue Repair. Samta began her career at LEK Consulting, providing strategic analysis to a number of healthcare and biotech clients. She received her MBA from the J.L. Kellogg Graduate School of Business and a B.A. from Princeton University.
Jean Balch is the Executive Administrator for Strand Therapeutics where she assists the leadership team and research staff members. She has decades of experience in startup, academic, and corporate environments, during which time she has facilitated productivity efforts to meet a wide range of targeted objectives. Jean spent over a decade with Bristol-Myers Squibb in support of research group projects and compliance activities, as well as group travel arrangements and events. Prior to her time with BMS, she handled a variety of administrative activities such as operations, HR, legal, and technical relations for several other startup companies, including: Advanced Inhalation Research, Pulmatrix, and Molten Metal Technology. Earlier in Jean’s career, she managed the Student Office for MIT’s Graduate Department of Chemical Engineering overseeing admissions, registration, recruiting, and financial support. Jean received her Bachelor’s Degree from Michigan State University. In the years since, she has studied management and earned professional certifications in both HR and paralegal activities.
Joseph Barberio is a biochemist and molecular biologist with a proven track record of solving complex problems with innovative solutions. He is the Director of mRNA Process Development at Strand Therapeutics and oversees Strand’s manufacturing strategy to support clinical development. With over fifteen years of industry experience, Joe specializes in process and analytical development and has extensive expertise in manufacturing of both viral and RNA based gene therapy medicinal products. The majority of Joseph’s career has been focused on building platforms for small biotech organizations. Most recently at bluebird bio, he constructed and led the mRNA process development team, a group designed to enable gene editing programs. Earlier in his career, Joe held process development roles at Moderna, Percivia, and Acceleron Pharma. In addition to his work at Strand, Joseph also serves on the Board of Directors of Sophie’s Hope Foundation, a non-profit charity supporting research for Glycogen Storage Disease (GSD). He received his B.A. in Biochemistry, Cellular and Molecular Biology at Connecticut College, graduating Cum Laude with distinction.
Tony joined Strand Therapeutics as a Laboratory Technician. He has worked in various Laboratory Operations environments such as Start-Up, Clean Room, and Animal Vivarium. Most recently Tony worked as a Laboratory Technician for Scholar Rock where he supported Inventory and Chemical Management, EHS, and Facilities Maintenance. He also supported Expansion Projects at Scholar Rock setting up a secondary laboratory, customizing Inventory and Equipment logistics. Tony enjoys working in the Biotechnology field because he can work and contribute to making people’s lives better.
Kavya Borde is an Associate Scientist for the Molecular Biology Department at Strand Therapeutics. She started out as an intern in the department and became part of the team in early 2021. She has previously worked as an undergraduate researcher in the regenerative cellular biology department at the University of Wisconsin-Madison and food microbiology department at Mahidol University, Thailand. She is currently supporting cell culture and molecular biology experiments as part of the in vitro molecular biology platform development efforts at Strand Therapeutics. She received her B.S. in Microbiology with a certificate in the science of fermented foods and beverages at the University of Wisconsin-Madison.
Tyler Cabral is the Talent Acquisition Manager at Strand Therapeutics. Tyler is an outgoing professional who is passionate about identifying and placing talent into functions that support the design, development and commercialization of novel therapeutics. After completing his undergraduate studies, Tyler worked in manufacturing at Organogenesis, a regenerative medicine biotech, where he supported the development and scale up of Organogenesis’ commercial products. He ultimately made the decision to transition into recruiting at Pharmalogics Recruiting, a retained recruiting agency that focused on providing recruitment services to life science organizations across the globe. He supported multiple clients ranging from small startup organizations to multinational biopharmaceutical corporations, and placed individuals in all areas of R&D, commercial, and corporate G&A. With his scientific background, recruiting skill set, and passion for helping others, Tyler oversees talent acquisition at Strand and streamlines hiring processes as the organization continues to grow. Tyler holds a B.S. in Biomedical Sciences from Quinnipiac University.
Aidan Coia is an Associate Scientist conducting mRNA/pDNA process development. He is working to scale mRNA production by optimizing processes related to both synthetic biology and mRNA development. Prior to joining Strand, Aidan worked in pharmaceutical drug development and, most recently, worked to develop high-throughput COVID-19 testing processes. He received his B.S. degree in cell and molecular biology/genetics from Boston University.
Rachel Eichman is an Associate Scientist for the Molecular Biology Department at Strand Therapeutics. In previous academic research, she leveraged molecular biology techniques for the creation of novel bacteria plasmids for both protein expression and validation of in-vivo active long-recognition endonucleases. She received her B.S. in Biomolecular and Chemical Engineering from Cornell University in Ithaca, NY.
Stephanie Esonwune is an Associate Scientist II for the Molecular Biology Department at Strand Therapeutics. She has previously worked for the Functional Genomics Platform at Whitehead Institute optimizing lentiviral transduction conditions in patient derived ovarian cell lines. She received her BA in Biochemistry & Molecular Biology and her MA in Biotechnology at Boston University.
Danny Gately is an Associate Scientist in Strand’s mRNA Process Development team. He is currently working to build Strand’s mRNA analytical and process development platforms and supporting process automation efforts. Danny is experienced in working with mRNA therapeutics. Before joining Strand in December 2020, he worked in mRNA analytical development at bluebird bio, where he helped to build the mRNA process and analytical platforms to a point of clinical readiness. Danny is a graduate of the University of Massachusetts Amherst, where he received his B.S. degree in Microbiology.
Moez Ghumman is currently an Associate Scientist in the mRNA Nanoparticle Formulation Development group at Strand Therapeutics. Moez completed both his Bachelor’s and Master’s in Pharmaceutical Sciences with a concentration in Pharmaceutics and Pharmacokinetics from the University of Rhode Island. Moez had an interest in drug development and dosage form design and worked for several months as an intern in the Formulation Laboratory at Rhodes Pharmaceuticals. Moez’s prior research experience was focused on developing a novel nanoparticle drug delivery system for treatment of idiopathic pulmonary fibrosis. Along with publishing his research in the European Journal of Pharmaceutics and Biopharmaceutics, Moez has been a presenting author at several conferences held by the Biomedical Engineering Society and American Association of Pharmaceutical Scientists.
Daniel Hartman is an Engineer, Data Analytics and Machine Learning at Strand Therapeutics. He completed his Bachelors in Biochemistry at Northeastern University. Prior to joining Strand Therapeutics, Dan worked in the Zupanc Neurobiology Laboratory at Northeastern, where he studied endogenous oscillators and the ionic mechanisms that drive their oscillation. He is proficient in exploring high-dimensional biological data sets and brings knowledge of high-performance computing to his role at Strand where he supports data-driven biological modeling using statistics and machine learning. Dan works primarily to design, build, and validate software tools for analyzing and optimizing mRNA therapeutics.
Tim Hayden is the Senior Director of Financial Planning & Analysis at Strand Therapeutics. He has nearly two decades of finance experience spanning pharma and biotech. Formerly, he worked at Johnson & Johnson, Sanofi, Pfizer, Esperion Therapeutics and TCR2. Throughout his tenure, he has supported early development all the way through launch and commercial success, (Xtandi, Bavencio, Nexletol, Nexlizet). Tim has effectively led co-promote alliances, regional partnerships, and various financing transactions. The majority of Tim’s career has been focused on leading finance to establish discipline, process, and planning recently in the therapeutic areas of oncology, cell therapy and cardiovascular disease. Most importantly working with leadership to make effective decisions around use of cash and capital structure management. He received his B.S. in Management and his M.B.A. from Fairleigh Dickinson University.
Michelle Kerns is an Associate Scientist, In Vivo Discovery at Strand Therapeutics. She has experience working as a biochemist and assisting with in vivo pharmacology studies, supporting academia and industry alike. Previously, she was at Agios Pharmaceuticals and UMass Medical Center. Michelle joined Strand to continue her passion of exploring novel therapeutics. She received her B.S. in Biochemistry from Worcester Polytechnic Institute.
Kunjan Khatri is an Engineer, Data Analytics and Machine Learning at Strand Therapeutics. Kunjan works closely with the drug discovery and platform teams to analyze biological data from a variety of sources and build machine learning-based tools for drug design. He is proficient in statistical methods and machine learning, including common software tools. Prior to joining Strand Therapeutics, Kunjan interned in the Computational Science team at the Jackson Laboratory, biomedical research institution working on omics data to apply genomics analysis and quantitative research. Kunjan received his M.S. in Data Science from Northeastern University.
Jaspreet Khurana is a molecular biologist with over 15 years of combined academia and industry research experience in target discovery and validation. He is skilled at mRNA therapeutics, genome engineering as well as next-generation sequencing. At Strand Therapeutics, he is leading the in vitro molecular biology platform, which encompasses vector development, mRNA production and in vitro POC studies for target validation. Previously, he was at Omega Therapeutics as the Senior Scientist in the Biology team. During his academic career, he elucidated novel functions for various epigenetic pathways including non-coding RNAs using cutting edge genomics. He received his Ph.D in Biomedical Sciences from University of Massachusetts Medical School, Worcester, followed by a postdoc focused on RNA biology and genomics at Princeton and Columbia Universities. He also holds a Masters in Biotechnology from Jawaharlal Nehru University (JNU), India. He has published several high profile peer- reviewed publications in journals such as Cell, Nature Structural and Molecular Biology, PLoS Biology, PLoS Genetics and has been cited more than 1200 times.
Alexander Lemaire is an experienced process and analytical development associate in Strand’s Process Development group. He’s tasked with building Strand’s mRNA production and analytical platform. Alexander has experience in developing robust analytical assays and release strategies for regulatory interactions and IND enabling activities. Additionally, Alexander prides himself on making processes and analytics higher throughput and scalable through the use of automation and robotics. Previously, Alexander was at bluebird bio, where he developed, qualified and implemented novel release assays to evaluate clinical grade mRNA. Alexander graduated with a B.S. in Biology.
Melissa Lucas is a Manager of Business Operations at Strand Therapeutics. Melissa has over 8 years’ experience in operations in multiple industries. She started her career in the United States Army at Joint Base Lewis McChord in Washington State as a Healthcare Specialist. She provided medical support to service members and civilians while providing oversight of day-to-day operations. After completing her contract in Washington, she was stationed at the US Army Research Institute of Environmental medicine as a Healthcare Supervisor and Project Manager. She coordinated and managed the medical evaluations and medical documentation requirements for research volunteers. Melissa also managed and supported all security elements in the company which included publication reviews, employee contracts, and vendor services. After leaving the service, Melissa transitioned to an Operations Specialist at Dakota Systems’ Inc. In this role, Melissa supported the Quality department in process improvement and development, root cause and data analysis, and all regulatory requirements. She also managed multiple complex projects that required constant oversight for success. Ultimately, Melissa made the decision to transition to the Biopharmaceutical Industry to follow her dream of improving people’s lives. With her vast experience in Operations, her passion to learn, and her desire to help people, Melissa will support day-to-day functions at Strand and develop, improve, and streamline all business operations. Melissa holds a B.A in Business Administration, Management from the University of Massachusetts, Amherst and is currently in the B.S. in Mechanical Engineering Technology at the University of Massachusetts, Lowell.
Ashoka Madduri is the Sr Director, Business Development at Strand Therapeutics. He is a biotech strategist with a demonstrated passion and success in building strategic alliances and investment opportunities across the biotech and pharma world. Prior to Strand, Ashoka was a Sr. Director of Corporate Strategy and BD at Aviceda Therapeutics where he worked with the executive team on corporate positioning for investment and strategic partnership opportunities. As a partner at Vestra Associates, he advised senior executives of start-ups on strategy, analysis for disease/drug development platforms, forging strategic alliances, and raising capital. At Wave Life Sciences, Ashoka was a Director of Strategy & Partnerships where he sought and established B2B collaborations to further the companies’ innovation and operations capabilities. Earlier, as VP of Innovation at Integrity Biochem, Ashoka led the integration of operations and research platforms acquired from HPPE, and advised on scientific innovations and strategies to drive sustainability. At HPPE, as the Director/Head of R&D, Ashoka set the scientific strategy of HPPE, developed the IP portfolio and oversaw the development across all of the company’s product platforms. He regularly participated in board meetings communicating technical updates to the board and investors. He worked in close conjunction with the business development teams and shared responsibility for all strategic partnership decisions. Ashoka received his Executive MBA from MIT Sloan, and has a PhD in Bio-organic Chemistry from the University of Groningen, The Netherlands, followed by post-doctoral research at Harvard Medical School.
Jacob is a Scientist working in the mRNA nanoparticle formulation development group at Strand Therapeutics. With 10 years’ experience within the pharmaceutical industry, Jacob has focused on lipid nanoparticle formulation, process development, and GMP manufacturing initiatives. He is tasked with scale-up activities for Strand’s lead LNP programs heading toward the clinic. Jacob previously worked at Beam Therapeutics & Intellia Therapeutics where he played crucial roles in formulation development, screening activities, and process scale-up for IND enabling studies, advancing non-viral delivery for lead CRISPR/cas9 and base editing programs. He has also worked within the oncology therapeutic space at Merrimack Pharmaceuticals where he focused on optimization and characterization of lead liposome delivery formulation and process development through late-stage clinical manufacturing. Jacob studied his M.S. at the University of Massachusetts.
Colleen is an Associate Scientist on the Molecular Biology team at Strand Therapeutics. She previously worked studying novel gene functions in the malaria causing parasite at Boston Children’s Hospital. Colleen is a graduate of Union College, where she received her B.S. degree in Biology.
Ashley Njiru is an Associate Scientist for the Molecular Biology Department at Strand Therapeutics. She has previously worked in developing gene editing constructs and dermatological cancer models at Brigham and Women’s Hospital. She received her B.S. in Molecular Biology at Massachusetts College of Pharmacy and Health Sciences University in Boston, MA.
Ashlesha is a cell and molecular biologist passionate about developing the next generation of cell and gene therapies. Her research expertise involves cell and gene engineering using systems such as viral vectors and gene editing platforms like CRISPR/Cas9 to deliver therapeutic cargo for translational applications in primary cells. As a Senior Scientist for Immune cell engineering at Strand, she is aiding the development of Strand’s unique mRNA-based cell therapy platform for applications such as CAR-T cells as cancer therapeutics. Before joining Strand, Ashlesha was working as a post-doctoral fellow in the lab of Dr. Michel Sadelain at the Memorial Sloan Kettering Cancer Center, New York, focusing on developing novel synthetic biology approaches to improve CAR-T cell therapy particularly for solid tumors. Her work also involved developing novel constructs for optimized, cell-type specific expression of beta globin in erythroid cells for application in gene therapy for beta thalassemia. She earned her Ph.D. in Biochemistry, Cell and Molecular Biology from Weill Cornell Medicine, Cornell University where she worked on identifying novel genomic locations for targeted CAR-T cell therapy using CRISPR/Cas9. She also holds a Master’s in Biotechnology from the University at Buffalo and a Bachelors in Pharmaceutical Sciences from University of Mumbai. She has authored and co-authored peer-reviewed publications in journals such as Nature and Nature Medicine and also has patents to her name based on her work.
Ryan Patenaude is an Associate Scientist, In Vivo Discovery at Strand Therapeutics. He joined in late 2021. He has previously worked in developing various animal models, cellular assays, and molecular biology assays as a research assistant at Boston Children’s Hospital, and as an undergraduate researcher at Beth Israel Deaconess Hospital. He received his B.S. in Biology, with a concentration in Biochemistry, from Emmanuel College.
Grishma is an Associate Scientist II in the mRNA evolution team. Previously, she was a co-op at Biogen in the Protein and Cell Engineering team. Her undergrad project ‘Comparative Evolution of marketed eye drop formulations’ increased her curiosity in research further. She realized that what people have achieved in the field of science is barely scratching the surface and there is a lot to come. Grishma received her M.S. in Pharmaceutical Sciences from Northeastern University and a bachelor’s degree in pharmacy from the University of Mumbai.
Hanna Scher is an Associate Scientist working in the mRNA LNP formulation development group at Strand Therapeutics. Prior to joining Strand, she worked on the mRNA analytical development team at Pfizer helping qualify different formulations and lipids for the Covid-19 vaccine. She also developed analytical platforms for the flu vaccine in order to qualify for clinical use. She received her B.S. in Chemical Engineering at the University of Massachusetts Amherst and is currently pursuing her M.S. in Biotechnology from Johns Hopkins University.
John Sexton is a synthetic biologist with deep expertise in genetic circuit design and a solid foundation in computational and programming methods and tools. Prior to Strand, he completed his Ph.D. and short postdoc at Rice University, where he designed and built genetic circuits to improve cell-cell communication in bacteria. He also co-developed an open-source software package for flow cytometry analysis, which is now used in academic and industrial labs around the world. His work has been featured in leading research journals including Molecular Systems Biology and ACS Synthetic Biology. Prior to graduate school, John was a Padawan at Ginkgo Bioworks. John also holds a B.S. in electrical and computer engineering and biomedical engineering from Carnegie Mellon University.
Aalok has been leading the Formulation and Delivery effort at Strand since June 2020. Aalok brings along more than 10 years of experience in lipid nanoparticle delivery working at leading gene therapy companies. Prior to Strand, he was at Beam Therapeutics where he was an integral part of Beam’s delivery efforts aimed at advancing base editing technology to cure liver diseases. Previously, he was at Intellia Therapeutics, where he was a key contributor in advancing CRIPSR/cas9 applications and demonstrated the first in-vivo proof of concept for the technology. Earlier in his career, he spent time at Dicerna Pharmaceuticals where he was on the team that advanced siRNA programs to the clinic. His broad exposure to multiple therapeutic modalities spanning protein, siRNA and mRNA gives him an impactful lens with which to address and solve scientific challenges facing the field of gene therapy delivery systems. Aalok received his M.S. in Drug Delivery from Northeastern University and B.S. in Pharmaceutical Science from Nirma University.
Kevin Shi is a Principal Scientist, Data Analytics and Machine Learning at Strand Therapeutics. Kevin's work spans mechanistic and machine learning-based modeling of synthetic biology circuits, analytics for high throughput experimentation, and optimization of drug properties. He also brings expertise in software development for automation and process analytics. Prior to joining Strand Therapeutics, Kevin headed the computational drug design and software development program at Mytide Therapeutics, a peptide drug discovery and manufacturing company. This work entailed building machine learning pipelines for process optimization and structure-guided peptide design and developing a fully automated peptide synthesis platform. Kevin received his Ph.D. in Bioengineering from MIT under the supervision of Prof. Bruce Tidor in the Department of Biological Engineering and the Computer Science and Artificial Intelligence Laboratory. His research focused on system biology for biochemical signaling pathways and optimal experimental design. He received his B.S. in Chemical Engineering from Caltech, where he also worked on antibody-drug conjugate design under the direction of Prof. Steve Mayo.
Anna Simon is a Scientist, in the Synthetic Biology group at Strand Therapeutics. Anna takes inspiration from nature to design new, technologically useful functions into biological molecules. In particular, Anna’s work has focused on combining rational design and synthetic evolution to design minimalist sets of nucleic acids and proteins that cooperate and assemble in response to changes in their environment. Before joining Strand Therapeutics, Anna was an Arnold O. Beckman Postdoctoral Fellow at the University of Texas at Austin, where she engineered natural systems into tools to create novel synthetic biosystems, specifically engineering bacterial retroelements for gene editing and evolution-inspired protein assembly strategies. She received a B.S. in Biological Engineering from MIT and a Ph.D. in Biochemistry and Molecular Biology from UC Santa Barbara. Anna has authored numerous publications, including in the journals Nature Biotechnology, Proceedings of the National Academy of Sciences USA, Angewandte Chemie, ACS Synthetic Biology, Nucleic Acids Research, and Nature Chemistry, where her publication was featured on the cover of the March 2019 issue.
Aidan Simpson is an Associate Scientist in Strand Therapeutics' Molecular Biology Department who started in November 2021. Aidan graduated from the Massachusetts Institute of Technology in 2021 with a B.S. in Biological Engineering and Business Management. During his undergrad at MIT, Aidan interned in the Weiss Lab and the Del Vecchio Lab, both of which focus on synthetic biology. He is currently supporting drug discovery at Strand by performing cell-based assays and molecular biology experiments.
Ryan is an immunologist focused on next-generation immune medicines for cancer and responsible for supporting Strand’s immuno-oncology programs. Prior to joining Strand, he was a postdoctoral fellow at Yale School of Medicine where he developed cutting edge ‘immune avatars’, an in vivo model system constructed from individual patients’ tumors and their immune systems to enable personalized parallel evaluation immunotherapy combinations. His research interests include T cells and how they adapt to different tissue microenvironments. Ryan earned his Ph.D. in Immunology at Rush University in Chicago, where he identified a novel approach to redirect T cells to mucosal tissues where they are positioned to serve as a barrier to infection. He also holds a M.S. in Biomedical Sciences from University of Texas, M. D. Anderson Cancer Center, and a B.S. in Cell & Molecular Biology from University of Northern Colorado. He has authored numerous publications, including in the journals Cell, Nature Medicine, Nature Communications, Blood, Cancer Discovery, Journal of Clinical Oncology, Cell Reports, Journal of Immunology, and has been collectively cited over 1000 times.
Zhijun Su is an associate scientist at Strand Therapeutics. She is currently supporting Strand’s cancer immunotherapy program. She is adept at RNA synthesis, immunological analyses, running mouse models, and keeping the lab organized. Prior to Strand, she worked at Koch Institute of Integrative Cancer Research at MIT, Irvine Lab, where she worked on a number of mouse animal studies, and supported cell culture and molecular biology experiments. She earned her B.S. in Biochemistry and Molecular Biology from the University of Massachusetts Amherst.
Tony Szeglowski is an Associate Scientist in the Synthetic Biology Department at Strand Therapeutics. He has previously worked on oligonucleotide therapeutics and technologies at Regeneron Pharmaceuticals, where he was key in establishing the Oligonucleotide Therapy Core. Tony is passionate about all things RNA and joined Strand to further explore and build novel mRNA therapies. He received his B.A. in Biological Sciences with research distinction from the University at Buffalo.
Wen Allen Tseng is a Principal Scientist in Synthetic Biology at Strand Therapeutics. Prior to joining Strand, he was in the Research and Development group at Solid Biosciences, a company focused on developing gene therapies for Duchenne muscular dystrophy. Before working in industry, Allen was a postdoctoral associate at the MIT Synthetic Biology Center, where he engineered mammalian cells with genetic circuits to control cellular processes such as antibody glycosylation. He obtained his B.S. in Biological Sciences from the University of Delaware and earned his Ph.D. in Experimental Pathology from Harvard University, where he studied the involvement of an innate immune danger-sensing pathway in age-related macular degeneration.
Weiyu is a Scientist, in the mRNA nanoparticle formulation development group at Strand Therapeutics. Her research expertise involves the development of functional drug/gene delivery systems. Weiyu received her Ph.D. in Pharmaceutical Sciences from the Ohio State University, where she worked on developing lipid nanoparticles for mRNA based therapeutics. She also holds an M.S. degree in Pharmaceutics and a B.S. degree in Pharmacy from Peking University Health Science Center. Weiyu has authored and co-authored peer-reviewed publications in journals, such as Nature Nanotechnology, Nature Cancer, Nature Biomedical Engineering, Science Advances, and Chemical Science and Biomaterials.